Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05904028 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Study acronym: AO
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Enrollment target: estimated 600 to confirmed 603
    • Study sites: 65 to 64
    v20
  2. Study sites: 64 to 65v19
  3. Study sites: 59 to 64v18
  4. Study sites: 57 to 59v17
  5. Study sites: 56 to 57v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 48 to 56v15
  2. Eligibility criteria expanded, about 23 words
    • Study description shortened, about 53 words
    • Site contacts updated at 12 of 48 sites
    v14
  3. Study sites: 46 to 48v13
  4. Study sites: 38 to 46v12
  5. Study sites: 36 to 38v11
  6. Eligibility criteria shortened, about 18 words
    • Site contacts updated at 10 of 36 sites
    v10
  7. Study sites: 34 to 36v9
  8. Study sites: 32 to 34v8
  9. Study description expanded, about 27 words
    • Site contacts updated at 2 of 32 sites
    v7
  10. Study sites: 29 to 32v6
  11. Study sites: 26 to 29v5
  12. Study sites: 13 to 26v4
  13. Trial status: Not Yet Recruiting to Recruitingv3
  14. Start date: Aug 1, 2023 to Nov 9, 2023
    • Primary and study completion dates: Jun 30, 2027 to Jul 30, 2027
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Trial Details
NCT Number NCT05904028
Lead Sponsor Jaeb Center for Health Research
Collaborators: National Institutes of Health (NIH), National Eye Institute (NEI), Juvenile Diabetes Research Foundation
Conditions
(from sponsor)		 Neovascular Age-related Macular Degeneration
Enrollment 603 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov